Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)

A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy

The LIFE study was conducted from 1995-2001. This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart. The results showed that after an average treatment time of 4.8 years, treatment that was based on losartan was better than treatment based on atenolol for reducing the risk of having a stroke. The main study results were published in Dahlof et al. Lancet 2002;359:995-1003.

Inclusion Criteria:

• Age 55 to 80 years
• Males and females
• Hypertension (160-200/95-115 mm Hg
• ECG evidence of left ventricular hypertrophy

Exclusion Criteria:

• Need for treatment with angiotensin converting enzyme inhibitors, or open- label angiotensin receptor blockers or beta-blockers
• Myocardial infarction or stroke within 6 months